The newly amended Medical Psilocybin Act would create a state supervised program granting psilocybin access — including take-home use for some — to patients with qualifying conditions.

Industry insiders weigh in on the growing pains of Oregon's regulated psilocybin program which has seen concerns raised about licensing fees and some service centers close.

Misleading headlines around New Jersey’s psilocybin pilot program reveal how misinformation and weak media literacy are distorting psychedelic policy debates nationwide.

Without deliberate policy solutions, state-based programs risk remaining narrow, unaffordable, and politically fragile. But if we can solve for affordability, the implications extend far beyond psychedelics.